Literature summary for 3.4.14.5 extracted from

Bergman, A.; Ebel, D.; Liu, F.; Stone, J.; Wang, A.; Zeng, W.; Chen, L.; Dilzer, S.; Lasseter, K.; Herman, G.; Wagner, J.; Krishna, R.
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers (2007), Biopharm. Drug Dispos., 28, 315-322.

Search for more literature for 3.4.14.5

Application

Application	Comment	Organism
medicine	dipeptidyl peptidase-4 inhibitor is approved in the United States for the treatment of type 2 diabetes. The absolute bioavailability of sitagliptin final market image tablets is approximately 87%. Food does not affect the pharmacokinetics of sitagliptin and therefore can be administered without regard to food generally well tolerated when administered orally or intravenously	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
sitagliptin	dipeptidyl peptidase-4 inhibitor approved in the United States for the treatment of type 2 diabetes. The absolute bioavailability of sitagliptin final market image tablets is approximately 87%. Sitagliptin is Food does not affect the pharmacokinetics of sitagliptin and therefore can be administered without regard to food generally well tolerated when administered orally or intravenously	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)